Product
CYAD-211
1 clinical trial
1 indication
Indication
Relapse/Refractory Multiple MyelomaClinical trial
Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory DiseaseStatus: Active (not recruiting), Estimated PCD: 2022-12-21